Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deprescribing in migraine
Paolo Martelletti, Michelangelo Luciani, Valerio Spuntarelli, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 6, pp. 623-625
Closed Access | Times Cited: 20

Showing 20 citing articles:

Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
Hannah A. Blair
CNS Drugs (2023) Vol. 37, Iss. 3, pp. 255-265
Open Access | Times Cited: 28
Inflammatory complications of CGRP monoclonal antibodies: a case series
Jason C. Ray, Penelope J. Allen, Ann Bacsi, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 46
Unmet Needs in the Acute Treatment of Migraine
Enrico Bentivegna, Silvia Galastri, Dilara Onan, et al.
Advances in Therapy (2023) Vol. 41, Iss. 1, pp. 1-13
Open Access | Times Cited: 11
The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosis
Alessandra Pistolesi, Alice Molli, Francesco De Cesaris, et al.
European Journal of Pharmacology (2025), pp. 177415-177415
Closed Access
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Recent advancements in tension-type headache: a narrative review
Enrico Bentivegna, Michelangelo Luciani, Vincenzo Paragliola, et al.
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 7, pp. 793-803
Closed Access | Times Cited: 22
Long-covid cognitive impairment: Cognitive assessment and apolipoprotein E (APOE) genotyping correlation in a Brazilian cohort
José Wagner Leonel Tavares-Júnior, Danilo Nunes Oliveira, Jean Breno Silveira da Silva, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 15
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10975-10975
Open Access | Times Cited: 14
Atogepant and Sumatriptan: No Clinically Relevant Drug–Drug Interactions in a Randomized, Open-Label, Crossover Trial
Ramesh Boinpally, Abhijeet Jakate, Matthew Butler, et al.
Pain Management (2021) Vol. 12, Iss. 4, pp. 499-508
Open Access | Times Cited: 20
Positioning the new drugs for migraine
Silvia Benemei, Enrico Bentivegna, Paolo Martelletti
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 1-3
Open Access | Times Cited: 12
Safety and tolerability of preventive treatment options for chronic migraine
Amanda Tinsley, John F. Rothrock
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 12, pp. 1523-1533
Closed Access | Times Cited: 14
Narrative-based medicine in headache disorders
Christian Lampl, Simona Sacco, Paolo Martelletti
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Headaches in general medical practice
Г. Р. Табеева
Terapevticheskii arkhiv (2022) Vol. 94, Iss. 1, pp. 141-121
Open Access | Times Cited: 8
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine
Fidel Dominique Festin Ambat, Enrico Bentivegna, Paolo Martelletti
BioDrugs (2022) Vol. 36, Iss. 3, pp. 337-339
Open Access | Times Cited: 7
Hormonal therapies in migraine management: current perspectives on patient selection and risk management
Enrico Bentivegna, Michelangelo Luciani, Francesco Scarso, et al.
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 12, pp. 1347-1355
Closed Access | Times Cited: 6
Recently approved and emerging drug options for migraine prophylaxis
Enrico Bentivegna, Michelangelo Luciani, Valeria Ferrari, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 11, pp. 1325-1335
Closed Access | Times Cited: 4
OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity
Dilara Onan, Enrico Bentivegna, Paolo Martelletti
Toxins (2022) Vol. 15, Iss. 1, pp. 29-29
Open Access | Times Cited: 4
What Is the Best Methodology for Headache or Migraine Research?
Cristina Gaglianone, Enrico Bentivegna, Paolo Martelletti
Headache (2023), pp. 1-21
Closed Access | Times Cited: 1
Evaluation of Readmissions after Discharged from Intensive Care Unit in Patients with Coronavirus Disease-2019
Merve Sena Baytar, Çağdaş Baytar
Deleted Journal (2022) Vol. 6, Iss. 1, pp. 53-57
Open Access
Reaching the Nadir of Medication Overuse in Chronic Migraine
Dilara Onan, William Wells-Gatnik, Paolo Martelletti
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 22, pp. 14696-14696
Open Access
Page 1

Scroll to top